Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’

Bibliographic Details
Main Author:	Xudong Zhu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/3/e011845.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu
by: Egbert F Smit, et al.
Published: (2025-07-01)

Response to: Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study’ by Wang
by: Egbert F Smit, et al.
Published: (2025-07-01)

Correspondence on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Smeenk et al
by: Bi-Cheng Wang
Published: (2025-07-01)

Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment  of Advanced Non-small Cell Lung Cancer
by: Ning WAN, et al.
Published: (2024-10-01)

Prognostic stratification through smoking status and cumulative smoking dose in advanced non-small cell lung cancer immunotherapy: a dose-dependent real-world analysis
by: Lan Yang, et al.
Published: (2025-08-01)

Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis
by: Yasuyuki Ikezawa, et al.
Published: (2024-07-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01)

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
by: Aida Piedra, et al.
Published: (2024-12-01)

A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer
by: Tao Han, et al.
Published: (2025-06-01)

Outcomes of Daily Dose versus Part-daily Dose Treatment for Lung Tuberculosis: A Real-World Database Study in an Indonesian Hospital
by: William William, et al.
Published: (2021-03-01)

Combined IVIG and High‐Dose Systemic Corticosteroids for the Management of Pembrolizumab‐Induced Cytokine Release Syndrome in Lung Adenocarcinoma
by: Cheng‐Yin Liu, et al.
Published: (2025-05-01)

Comparative Analysis of Pembrolizumab Dosing Schedules in the Adjuvant Treatment of Malignant Melanoma
by: Y. Ahmed, et al.
Published: (2024-01-01)

Pulmonary Nocardiosis in a Non-Small Cell Lung Cancer Patient Being Treated for Pembrolizumab-Associated Pneumonitis
by: Liam Quartermain, et al.
Published: (2024-10-01)

ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER.
by: D. V. Gogolin, et al.
Published: (2016-02-01)

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01)

Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial
by: Abideen Salako, et al.
Published: (2025-07-01)

Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non–Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score–Matched Analysis
by: Praveen Kumar Marimuthu, et al.
Published: (2025-04-01)

The effect of the relative dose intensity of chemoradiotherapy on the effectiveness of therapy of locally advanced unresectable non-small cell lung cancer
by: A. E. Glukhareva, et al.
Published: (2024-03-01)

The Problem of Bicenter and Isochronicity for a Class of Quasi Symmetric Planar Systems
by: Du Chaoxiong
Published: (2014-01-01)

Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-01-01)

Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer
by: Jennifer D. Deem, et al.
Published: (2025-04-01)

Correction: Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial
by: Abideen Salako, et al.
Published: (2025-08-01)

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial
by: Albrecht Stenzinger, et al.
Published: (2025-08-01)

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
by: Chad Tang, et al.
Published: (2020-10-01)

Comment on: Toward an optimal contraception dosing strategy.
by: Giuseppe Benagiano, et al.
Published: (2024-12-01)

Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany
by: Alastair Greystoke, et al.
Published: (2025-05-01)

Steroid-Refractory Immune-Related Hepatitis Caused by Pembrolizumab with Stage IVB Non-Small Cell Lung Cancer: A Case Report
by: Tomomi Hamaguchi, et al.
Published: (2024-12-01)

Dysbiosis in the Gut Microbiome of Pembrolizumab‐Treated Non‐Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling
by: Haris Charalambous, et al.
Published: (2025-05-01)

Analysis of high-dose tamoxifen therapy efficiency in complex treatment of patients with stage III-IV non-small cell lung cancer
by: A. I. Shevchenko, et al.
Published: (2012-12-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
by: Ji Eun Shin, et al.
Published: (2025-02-01)

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China
by: Guangming Tian, et al.
Published: (2025-05-01)

Response to comment on: Toward an optimal contraception dosing strategy.
by: Brenda Lyn A Gavina, et al.
Published: (2024-12-01)

Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study
by: Stéphane Renaud, et al.
Published: (2025-05-01)

A Single Dose Oral Azithromycin versus Intramuscular Benzathine Penicillin for the Treatment of Yaws-A Randomized Non Inferiority Trial in Ghana.
by: Cynthia Kwakye-Maclean, et al.
Published: (2017-01-01)

Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report
by: Yuya Ashitomi, et al.
Published: (2020-08-01)

Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients
by: Daniela Lamorte, et al.
Published: (2025-06-01)

EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study
by: Sen Yang, et al.
Published: (2025-05-01)

Analysis of advanced non-small cell lung cancer course during high dose antiestrogen therapy use in complex chemoradiotherapy treatment of patients
by: A. V. Kadzhoian
Published: (2014-12-01)

Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’

Similar Items

Similar Items